DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
ATN-161 is an investigational drug.
There have been 21 clinical trials for ATN-161. The most recent clinical trial was a Phase 2 trial, which was initiated on November 15th 2018.
The most common disease conditions in clinical trials are Acute Kidney Injury, HIV Infections, and Renal Insufficiency. The leading clinical trial sponsors are Attenuon, Westat, and Ablynx.
There are eighteen US patents protecting this investigational drug and two hundred and forty-six international patents.
Recent Clinical Trials for ATN-161
|N-Acetyl Cysteine in the Prevention of Contrast Induced Nephropathy in Cirrhosis of Liver-NEPHRO Trial||Institute of Liver and Biliary Sciences, India||N/A|
|FURosemide Stress Test to Predict Need of Renal Replacement THERapy in Ischemic Acute Tubular Necrosis in ICU||Assistance Publique - Hôpitaux de Paris||Phase 4|
|Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In||Roche Pharma AG||Phase 1/Phase 2|
Top disease conditions for ATN-161
Top clinical trial sponsors for ATN-161
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|ATN-161||Start Trial||Fluorinated integrin antagonists||SciFluor Life Sciences, Inc. (Cambridge, MA)||Start Trial|
|ATN-161||Start Trial||Nonanoic and decanoic acid derivatives and uses thereof||SciFluor Life Sciences, Inc. (Cambridge, MA)||Start Trial|
|ATN-161||Start Trial||Method of making tetrahydronaphthyridinyl nonanoic acid compounds||SciFluor Life Sciences, Inc. (Cambridge, MA)||Start Trial|
|ATN-161||Start Trial||Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof||SciFluor Life Sciences, Inc. (Cambridge, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|